Genfit S.A. (EPA:GNFT)

Market Cap	548.75M +202.3%
Revenue (ttm)	65.43M -7.4%
Net Income	-85.97M
EPS	-1.72
Shares Out	49.80M
PE Ratio	n/a
Forward PE	61.12
Dividend	n/a
Ex-Dividend Date	n/a

Volume	283,691
Open	11.20
Previous Close	11.02
Day's Range	10.44 - 11.20
52-Week Range	3.05 - 11.10
Beta	1.12
Analysts	Strong Buy
Price Target	14.00 (+32.08%)
Earnings Date	Sep 29, 2026

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patien...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 188
• Stock Exchange: Euronext Paris
• Ticker Symbol: GNFT

Analyst Summary

According to 4 analysts, the average rating for GNFT stock is "Strong Buy." The 12-month stock price target is €14.00, which is an increase of 32.08% from the latest price.

Price Target

€14.00

(32.08% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 24, 2026

Data Sources Report a data error